

EnzymaticTherapy[®]
NATURAL MEDICINES™

7440 '02 SEP 17 P2:03

August 9, 2002

Office of Special Nutritionals (HFS-450)
Center for Food Safety and Applied Nutrition
U. S. Food and Drug Administration
5100 Paint Branch Parkway
College Park, MD 20740-3835

RECEIVED
AUG 20 2002
BY:

RE: Label Claims/Disclaimers

Dear Sir/Madam:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a manufacturer and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product.

COMPANY	PRODUCT NAME	DIETARY INGREDIENTS	STATEMENTS
Enzymatic Therapy, Inc.	Doctor's Choice for Women™	Vitamin A, Vitamin C, Vitamin D, Vitamin E, Vitamin K, Thiamin, Riboflavin, Niacin, Vitamin B6, Folic Acid, Vitamin B12, Biotin, Pantothenic Acid, Calcium, Iron, Phosphorus, Iodine, Magnesium, Zinc, Selenium, Copper, Manganese, Chromium, Molybdenum, Sodium, Potassium, Choline Bitartrate, Black Tea Leaf Extract, Cherry Fruit Extract, Green Tea Leaf Extract, Inositol, Ginger Rhizome Extract, Cranberry Fruit Extract, Chaste Tree Berry Extract, Grape Seed Extract, Bilberry Fruit Extract, Boron, Lutein, Silicon, Vanadium, Zeaxanthin	Doctor's Choice for Women provides iron and more than 35 other key ingredients for daily energy and essential nutrition*, including: Chaste tree berry extract (20 mg) to support the production of progesterone, ease PMS symptoms, and promote healthy menstrual cycles.*

825 Challenger Drive
Green Bay, WI 54311-8328
Ph: 920-469-1313
Fax: 888-570-6460
www.enzy.com


975 0162

LET 10934

DC for Women 8c

81634

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By: 
Robert C. Doster

Title: Senior Vice President of Scientific Affairs

Date: 8/9/02

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs at (920) 406-3608.

Sincerely,



Michael P. Devereux
Chief Financial Officer